Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Aylin Oommen Jose"'
Autor:
Shabir A Madhi, Dhayendre Moodley, Sherika Hanley, Moherndran Archary, Zaheer Hoosain, Umesh Lalloo, Cheryl Louw, Lee Fairlie, Leon Frederik Fouche, Mduduzi S L Masilela, Nishanta Singh, Coert Grobbelaar, Khatija Ahmed, Gabriella Benadé, Sutika Bhikha, As'ad Ebrahim Bhorat, Qasim Bhorat, Natasha Joseph, Keertan Dheda, Aliasgar Esmail, Sharne Foulkes, Ameena Goga, Aylin Oommen Jose, Gertruida Kruger, Dishiki J Kalonji, Natasha Lalloo, Johan J Lombaard, Anthonet Lombard Koen, Angelique Kany Luabeya, Rosie Mngqibisa, Friedrich G Petrick, Annah Pitsi, Michele Tameris, Asha Thombrayil, Pieter-Louis Vollgraaff, Shane Cloney-Clark, Mingzhu Zhu, Chijioke Bennett, Gary Albert, Emmanuel Faust, Joyce S Plested, Lou Fries, Andreana Robertson, Susan Neal, Iksung Cho, Greg M Glenn, Vivek Shinde
Publikováno v:
The Lancet HIV. 9:e309-e322
There is a paucity of data on COVID-19 vaccines in people living with HIV-1, who could be at increased risk of severe illness and death from COVID-19. We evaluated the safety and immunogenicity of a Matrix-M adjuvanted recombinant spike protein nanop
Autor:
Anthonet L. Koen, Alane Izu, Vicky Baillie, Gaurav Kwatra, Clare L. Cutland, Lee Fairlie, Sherman D. Padayachee, Keertan Dheda, Shaun L. Barnabas, Qasim Ebrahim Bhorat, Carmen Briner, Khatija Ahmed, Sutika Bhikha, Jinal N. Bhiman, Jeanine du Plessis, Aliasgar Esmail, Elizea Horne, Shi-Hsia Hwa, Aylin Oommen-Jose, Teresa Lambe, Matt Laubscher, Mookho Malahleha, Gabriella Benade, Shakeel McKenzie, Suzette Oelofse, Faeezah Patel, Sureshnee Pillay, Sarah Rhead, Hylton Rodel, Carol Taoushanis, Houriiyah Tegally, Asha Thombrayil, Tonya L. Villafana, Sarah Gilbert, Andrew J. Pollard, Shabir A. Madhi
In this South African phase 1/2b study, we demonstrated vaccine efficacy (VE) of two doses of AZD1222 for asymptomatic and symptomatic SARS-CoV-2 infection: 90.6% against wild-type and 77.1% against the Delta variant ≥9 months after vaccination. VE
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::90f5a6d20644392d1f0fb82c06d8b6c8
https://doi.org/10.1101/2022.07.18.22277743
https://doi.org/10.1101/2022.07.18.22277743
Autor:
Leon Fouche, Greg Glenn, Susan Neal, Chijioke Bennett, Anthonet Koen, Tulio de Oliveira, Andreana Robertson, Asha Thombrayil, Natasha Lalloo, Lee Fairlie, Gary Albert, Iksung Cho, Mingzhu Zhu, Aylin Oommen-Jose, Zaheer Hoosain, Lou Fries, Sherika Hanley, Vicky L Baillie, Moherndran Archary, As'Ad E. Bhorat, Michele Tameris, Aliasgar Esmail, Pieter Louis Vollgraaff, Shabir A. Madhi, Filip Dubovsky, Sutika Bhikha, Friedrich G. Petrick, Annah Pitsi, Sharne Foulkes, Nazira Carrim-Ganey, Keertan Dheda, Ameena Ebrahim Goga, Gertruida Kruger, Angelique Kany Kany Luabeya, Joyce S. Plested, Dhayendre Moodley, Emmanuel Faust, Nishanta Singh, Q E Bhorat, Coert Grobbelaar, Shane Cloney-Clark, Umesh G. Lalloo, Johan Lombaard, Vivek Shinde, Mduduzi Masilela, Khatija Ahmed, Gabriella Benade, Cheryl Louw, Rosie Mngqibisa
Publikováno v:
The New England Journal of Medicine
BACKGROUND: The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants threatens progress toward control of the coronavirus disease 2019 (Covid-19) pandemic. In a phase 1-2 trial involving healthy adults, the NVX-CoV2373 n
Autor:
Johan Vekemans, Elizea Horne, Tandile Hermanus, Andrew Moultrie, Shabir A. Madhi, Teresa Lambe, Alane Izu, Clare L. Cutland, Faeezah Patel, Samuel van Eck, Merryn Voysey, Sarah C. Gilbert, Ayanda Nzimande, Asha Thombrayil, Carol Taoushanis, Shaun Barnabas, Vicky L. Baillie, Penny L. Moore, S Rhead, Mduduzi Masilela, Prudence Kgagudi, Tonya Villafana, Andrew J. Pollard, Thandeka Moyo-Gwete, Parvinder K. Aley, Anthonet Koen, Christian Kabasele Mukendi, S D Padayachee, Sutika Bhikha, Amit J Nana, Lee Fairlie, Carmen Briner, Keertan Dheda, Masebole Masenya, Q E Bhorat, Gaurav Kwatra, Aylin Oommen Jose
Coronavirus disease 2019 (COVID-19) is a public health emergency of international concern1. People living with HIV (PLWH) are at increased risk for adverse COVID-19 outcomes compared with HIV-negative individuals2-5, and are a high-risk group for COV
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9fbd94a0a264dcacff563e13a4303278
https://doi.org/10.21203/rs.3.rs-322470/v1
https://doi.org/10.21203/rs.3.rs-322470/v1
Autor:
Mduduzi Lawrance Sandile Masilela, Sherika Hanley, Asha Thombrayil, As’ad E. Bhorat, Nazira Carrim-Ganey, Sutika Bhikha, Natasha Lalloo, Gary Albert, Filip Dubovsky, Mingzhu Zhu, Dhayendre Moodley, Friedrich G. Petrick, Gregory M. Glenn, Tulio de Oliveira, Vicky L Baillie, Joyce S. Plested, Emmanuel Faust, Lee Fairlie, Zaheer Hossain, Jonah J Lombaard, Shane Cloney-Clark, Aylin Oommen Jose, Umesh G. Lalloo, Shabir A. Madhi, Lou Fries, Moherndran Archary, Ameena Ebrahim Goga, Leon Fouche, Andreana Robertson, Gertruida Kruger, Coert Grobbelaar, Pieter-Louis Vollgraaff, Susan Neal, Anthonet Koen, Annah Pitsi, Sharne Foulkes, Angelique Kany Kany Luabeya, Iksung Cho, Aliasgar Esmail, Chijioke Bennett, Michele Tameris, Cheryl Louw, Rosie Mngqibisa, Nishanta Singh, Q E Bhorat, Keertan Dheda, Khatija Ahmed, Gabriella Benade, Vivek Shinde
BackgroundThe emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants threatens progress toward control of the Covid-19 pandemic. Evaluation of Covid-19 vaccine efficacy against SARS-CoV-2 variants is urgently needed to inf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3c27c2860e4552b6b30c4cd64d893011
https://doi.org/10.1101/2021.02.25.21252477
https://doi.org/10.1101/2021.02.25.21252477
Autor:
Merryn Voysey, Gaurav Kwatra, Elizabeth J. Kelly, Eck Sv, Houriiyah Tegally, Alex Sigal, Oelofse S, Shaun Barnabas, C Taoushanis, de Oliveira T, Hylton Errol Rodel, Tonya Villafana, M M Groenewald, Aylin Oommen Jose, Teresa Lambe, Alane Izu, Masebole Masenya, Shi-Hsia Hwa, A Moultrie, K Molapo, Keertan Dheda, Plessis Jd, Nicholas M. Durham, Anthonet Koen, Penelope L. Moore, Mduduzi Masilela, Constantinos Kurt Wibmer, Sarah C. Gilbert, Khatija Ahmed, Jinal N. Bhiman, Lee Fairlie, Carmen Briner, Bhikha S, S D Padayachee, As’ad E. Bhorat, E Horne, Clare L. Cutland, Q E Bhorat, F Patel, Parvinder K. Aley, Shabir A. Madhi, Aliasgar Esmail, Asha Thombrayil, Andrew J. Pollard, L Rossouw, M Malahleha, McKenzie S, Sureshnee Pillay, S Rhead, Baillie, Laubscher M
BackgroundAssessing safety and efficacy of Covid-19 vaccines in different populations is essential, as is investigation of efficacy against emerging SARS-CoV-2 variants of concern including the B.1.351 (501Y.V2) variant first identified in South Afri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7c6644fd2054776a42119b26d4c68333
https://doi.org/10.1101/2021.02.10.21251247
https://doi.org/10.1101/2021.02.10.21251247